Safety, Tolerability and Efficacy of ICV AX 250 Treatment in MPS IIIB -OLE
Condition(s) studied
Investigational drug(s) / intervention(s)
AX 250: biweekly infusion by intracerebroventricular (ICV) infusion
Study summary
This is a Phase 3B/4, multicenter, multinational, open label study to further evaluate intracerebroventricular (ICV) delivered AX 250 treatment in MPS IIIB subjects that complete Study 250-202 for up to an additional 3 years (144 weeks) of treatment with AX 250 administered by ICV infusion every other week. Subjects will be evaluated for neurocognitive function, communication, adaptive behavior, quality of life, imaging characteristics and biochemical markers of disease burden. Safety will be assessed by adverse events, clinical labs, and physical exams.
Eligibility
Primary outcome measure(s)
- Primary - neurocognition — baseline to 144 weeks of treatment
the rate of change in score from neurocognitive assessment using validated scale
Trial sites (6)
| Facility | City | Region | Status |
|---|---|---|---|
| UCSF Benioff Children's Hospital Oakland | Oakland | California | |
| UPMC Children's Hospital Pittburgh | Pittsburgh | Pennsylvania | |
| Fundación Cardio Infantil - Instituto de Cardiología | Bogotá | Colombia | |
| University Medical Center Hamburg-Eppendorf | Hamburg | Germany | |
| Gazi University Faculty of Medicine | Ankara | Turkey (Türkiye) | |
| Great Ormond Street Hospital For Children, NHS Foundation Trust | London | United Kingdom |
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT05492799 on ClinicalTrials.gov ↗ ← All trials in the USA